Eloxx Pharmaceuticals annual shares outstanding
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Shares Outstanding History (ELOX)
Eloxx Pharmaceuticals reported 435,432 shares outstanding at the end of fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 435,432 | 114,180 | +35.54% |
| 2024 | 2024-12-31 | 321,252 | 35,532 | +12.44% |
| 2023 | 2023-12-31 | 285,720 | 88,778.545 | +45.08% |
| 2022 | 2022-12-31 | 196,941.455 | 9.818 | +0.00% |
| 2021 | 2021-12-31 | 196,931.636 | 105,665.302 | +115.78% |
| 2020 | 2020-12-31 | 91,266.334 | 287.327 | +0.32% |
| 2019 | 2019-12-31 | 90,979.007 | 9,478.748 | +11.63% |
| 2018 | 2018-12-31 | 81,500.259 | 18,937.218 | +30.27% |
| 2017 · Dec 31 | 2017-12-31 | 62,563.041 | 53,005.591 | +554.60% |
| 2017 · Jun 30 | 2017-06-30 | 66,369.998 | 19,787.305 | +42.48% |
| 2016 · Dec 31 | 2016-12-31 | 9,557.45 | −36,853.023 | −79.41% |
| 2016 · Jun 30 | 2016-06-30 | 46,582.693 | 3,962.664 | +9.30% |
| 2015 · Dec 31 | 2015-12-31 | 46,410.473 | — | — |
| 2015 · Jun 30 | 2015-06-30 | 42,620.03 | 11,151.027 | +35.43% |
| 2014 | 2014-06-30 | 31,469.002 | 26,305.225 | +509.42% |
| 2013 | 2013-06-30 | 5,163.777 | 3,024.857 | +141.42% |
| 2012 | 2012-06-30 | 2,138.92 | 371.427 | +21.01% |
| 2011 | 2011-06-30 | 1,767.493 | — | — |
Eloxx Pharmaceuticals quarterly shares outstanding
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 4.0M | — | — |
| Q1 2026 | 2026-03-31 | 461,132 | — | — |
| Q4 2025 | 2025-12-31 | 435,432 | — | — |
| Q4 2023 | 2023-12-31 | 285,720 | 88,778.545 | +45.08% |
| Q3 2023 | 2023-09-30 | 196,941.455 | −4.502 | −0.00% |
| Q2 2023 | 2023-06-30 | 196,941.455 | −4.502 | −0.00% |
| Q1 2023 | 2023-03-31 | 196,941.455 | 2.616 | +0.00% |
| Q4 2022 | 2022-12-31 | 196,941.455 | 9.818 | +0.00% |
| Q3 2022 | 2022-09-30 | 196,945.957 | 917.855 | +0.47% |
| Q2 2022 | 2022-06-30 | 196,945.957 | 1,032.85 | +0.53% |
| Q1 2022 | 2022-03-31 | 196,938.839 | 105,541.398 | +115.48% |
| Q4 2021 | 2021-12-31 | 196,931.636 | 105,665.302 | +115.78% |
| Q3 2021 | 2021-09-30 | 196,028.102 | 104,776.898 | +114.82% |
| Q2 2021 | 2021-06-30 | 195,913.107 | 104,696.539 | +114.78% |
| Q1 2021 | 2021-03-31 | 91,397.441 | 203.227 | +0.22% |
| Q4 2020 | 2020-12-31 | 91,266.334 | 287.327 | +0.32% |
| Q3 2020 | 2020-09-30 | 91,251.205 | 392.9 | +0.43% |
| Q2 2020 | 2020-06-30 | 91,216.568 | 501.414 | +0.55% |
| Q1 2020 | 2020-03-31 | 91,194.214 | 9,499.65 | +11.63% |
| Q4 2019 | 2019-12-31 | 90,979.007 | 9,478.748 | +11.63% |
| Q3 2019 | 2019-09-30 | 90,858.305 | 11,029.114 | +13.82% |
| Q2 2019 | 2019-06-30 | 90,715.155 | 11,466.405 | +14.47% |
| Q1 2019 | 2019-03-31 | 81,694.564 | 19,131.523 | +30.58% |
| Q4 2018 | 2018-12-31 | 81,500.259 | 18,937.218 | +30.27% |
| Q3 2018 | 2018-09-30 | 79,829.191 | −37,022.202 | −31.68% |
| Q2 2018 | 2018-06-30 | 79,248.75 | 12,878.752 | +19.40% |
| Q1 2018 · Mar 31 | 2018-03-31 | 62,563.041 | 1,379.959 | +2.26% |
| Q4 2017 · Dec 31 | 2017-12-31 | 62,563.041 | 53,005.591 | +554.60% |
| Q1 2018 · Sep 30 | 2017-09-30 | 116,851.393 | 70,268.7 | +150.85% |
| Q4 2017 · Jun 30 | 2017-06-30 | 66,369.998 | 19,787.305 | +42.48% |
| Q1 2017 · Mar 31 | 2017-03-31 | 61,183.082 | 14,772.609 | +31.83% |
| Q4 2016 · Dec 31 | 2016-12-31 | 9,557.45 | −36,853.023 | −79.41% |
| Q1 2017 · Sep 30 | 2016-09-30 | 46,582.693 | 246.764 | +0.53% |
| Q4 2016 · Jun 30 | 2016-06-30 | 46,582.693 | 3,962.664 | +9.30% |
| Q1 2016 · Mar 31 | 2016-03-31 | 46,410.473 | 14,648.791 | +46.12% |
| Q4 2015 · Dec 31 | 2015-12-31 | 46,410.473 | 14,895.411 | +47.26% |
| Q1 2016 · Sep 30 | 2015-09-30 | 46,335.93 | 14,866.927 | +47.24% |
| Q4 2015 · Jun 30 | 2015-06-30 | 42,620.03 | 11,151.027 | +35.43% |
| Q3 2015 | 2015-03-31 | 31,761.682 | 16,085.068 | +102.61% |
| Q2 2015 | 2014-12-31 | 31,515.061 | 20,248.527 | +179.72% |
| Q1 2015 | 2014-09-30 | 31,469.002 | 26,132.164 | +489.66% |
| Q4 2014 | 2014-06-30 | 31,469.002 | 26,305.225 | +509.42% |
| Q3 2014 | 2014-03-31 | 15,676.614 | 12,336.266 | +369.31% |
| Q2 2014 | 2013-12-31 | 11,266.534 | 8,608.005 | +323.79% |
| Q1 2014 | 2013-09-30 | 5,336.839 | 2,683.357 | +101.13% |
| Q4 2013 | 2013-06-30 | 5,163.777 | 3,024.857 | +141.42% |
| Q3 2013 | 2013-03-31 | 3,340.347 | 1,252.343 | +59.98% |
| Q2 2013 | 2012-12-31 | 2,658.529 | 820.701 | +44.66% |
| Q1 2013 | 2012-09-30 | 2,653.481 | 842.217 | +46.50% |
| Q4 2012 | 2012-06-30 | 2,138.92 | 371.427 | +21.01% |
| Q3 2012 | 2012-03-31 | 2,088.004 | — | — |
| Q2 2012 | 2011-12-31 | 1,837.828 | — | — |
| Q1 2012 | 2011-09-30 | 1,811.264 | — | — |
| Q4 2011 | 2011-06-30 | 1,767.493 | — | — |
Eloxx Pharmaceuticals shares outstanding trends
Over the last five fiscal years, Eloxx Pharmaceuticals's shares outstanding moved from 91,266.334 to 435,432, a change of 344,165.666. The latest reported quarter, Q2 2026, shows 4.0M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...
